Vaccine Design and Testing – News and Features

Publication describes the use of RoboSep® to isolate CD4+ and CD8+ T cells.

Entry into Phase I marks a significant milestone for Genticel, which completed a EUR 13.1 million fund-raising in February 2010.

The acquisition gives Encorium capabilities to run clinical trials in South America, India and Asia Pacific.

Discovery to advance HIV vaccine design, antibody therapy for other diseases.

Using the HuALN technology AFFiRiS anticipates accelerating the progression of its human vaccine candidates into clinical trials.

A first-of-a-kind, plant-based vaccine factory, takes advantage of plant viral vector technology developed by Fraunhofer CMB for the biopharmaceutical company iBio.

Izon Science will unveil its latest breakthrough in nanoparticle analysis in the US this week.

Finding looks at clade C gp120; also reveals unusual autoreactivity between 21c antibody and CD4 receptor.

NanoSight helps the research group to focus on vaccine delivery and on protein formulation and characterization with respect to immunogenicity.

IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer